From Laboratory To Launchpad: Japan's Cell And Gene Therapy Ecosystem Hits Its Stride

By H. Deborah Chen, Kang Liu, Contributing authors: Yasuhiro Oshima, Koji Kubpta, AGC Biologics; Andrew Fleury, John Ng, Dark Horse Consulting Group

Japan's academic strength in regenerative medicine has long been clear. Whether that strength can become a sustainable commercial ecosystem is less settled.

Authors H. Deborah Chen and Kang Liu, with contributors from AGC Biologics and Dark Horse Consulting Group, trace the regulatory mechanisms, national strategy, capital programs, and manufacturing build-out behind recent progress, including conditional approval of two first-of-a-kind iPSC-derived therapies. They also weigh what still holds the ecosystem back, from late-stage financing gaps to language barriers, and outline regulatory, manufacturing, clinical, and entry-strategy considerations for developers weighing Japan.

Explore the analysis to see where the opportunity is real and where it demands careful planning.